Both inhibitors dampen PAK4 activity, thereby mitigating molecular signaling implicated in the cell cycle and metastatic progression, downregulating pivotal signaling pathways involved in tumorigenesis and progression, and consequently fostering potent anti-tumor and metastatic attributes [138,139]. This evidence concerns the gene PAK4 and neoplasm.